EA201990300A1 - Антитела к вирусу зика и способы их применения - Google Patents

Антитела к вирусу зика и способы их применения

Info

Publication number
EA201990300A1
EA201990300A1 EA201990300A EA201990300A EA201990300A1 EA 201990300 A1 EA201990300 A1 EA 201990300A1 EA 201990300 A EA201990300 A EA 201990300A EA 201990300 A EA201990300 A EA 201990300A EA 201990300 A1 EA201990300 A1 EA 201990300A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
zikv
methods
application
bind
Prior art date
Application number
EA201990300A
Other languages
English (en)
Inventor
Кристос Киратсоус
Уилльям Олсон
Питер Мэйсон
Original Assignee
Ридженерон Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз Инк. filed Critical Ридженерон Фармасьютикалз Инк.
Priority claimed from PCT/US2017/042447 external-priority patent/WO2018017497A1/en
Publication of EA201990300A1 publication Critical patent/EA201990300A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В данном изобретении предложены моноклональные антитела или их антигенсвязывающие фрагменты, которые связываются с гликопротеинами ZIKV, фармацевтические композиции, содержащие указанные антитела и способы применения. Антитела по изобретению полезны для ингибирования или нейтрализации активности ZIKV, тем самым обеспечивая средство для лечения или профилактики инфекции ZIKV у людей. В некоторых вариантах реализации изобретение относится к применению одного или более антител, которые связываются с ZIKV для предотвращения прикрепления и/или входа вируса в клетки-хозяева. Антитела по изобретению могут применяться профилактически или терапевтически и могут применяться отдельно или в комбинации с одним или более другими противовирусными агентами или вакцинами.
EA201990300A 2017-03-22 2017-07-17 Антитела к вирусу зика и способы их применения EA201990300A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762474753P 2017-03-22 2017-03-22
PCT/US2017/042447 WO2018017497A1 (en) 2016-07-18 2017-07-17 Anti-zika virus antibodies and methods of use

Publications (1)

Publication Number Publication Date
EA201990300A1 true EA201990300A1 (ru) 2019-06-28

Family

ID=66998676

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990300A EA201990300A1 (ru) 2017-03-22 2017-07-17 Антитела к вирусу зика и способы их применения

Country Status (1)

Country Link
EA (1) EA201990300A1 (ru)

Similar Documents

Publication Publication Date Title
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
WO2020106358A8 (en) Novel anti-zika virus antibodies and uses thereof
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA201990222A1 (ru) Антитела к o2 и пути их применения
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
PH12017502356B1 (en) Immunoglobulin single variable domain antibody against rsv prefusion f protein
MX2021004356A (es) Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
EA202092265A1 (ru) Антитела против cd137 для комбинации с антителами против pd-l1
EA201990300A1 (ru) Антитела к вирусу зика и способы их применения
EA201792482A1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа
EA202191973A2 (ru) Человеческие антитела к гликопротеину вируса эбола
EA202090583A1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии
MA40375A1 (fr) Anticorps humains contre l'hémagglutinine de la grippe